CompletedPhase 2

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

United States30 participantsStarted 2001-09

Plain-language summary

This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Intraventricular hemorrhage (IVH) confirmed by CT scan * More than 12 hours post bleed * Hematoma size stable by CT scan * Post-IVH catheter CT scan * Able to begin study within 24 hours of bleed Exclusion criteria: * Infratentorial bleed * Supratentorial bleed greater than 30 cc * Unclipped aneurysm suspected * Arteriovenous malformation suspected * Any severe, complicating illness (e.g., AIDS or DNR) * Cardiovascular parameters that could confound study (e.g., myocardial infarction, pulmonary emboli, systemic fibrinolysis) * Active internal bleeding * Requirement for heparin doses greater than 10,000 U/day * Concurrent coumadin * Known allergy to rt-PA * Pregnancy

Trial details

NCT IDNCT00029315

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Cerebral Hemorrhage trials